Marinus Pharmaceuticals (MRNS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MRNS Stock Forecast

Marinus Pharmaceuticals stock forecast is as follows: an average price target of $3.67 (represents a 1093.50% upside from MRNS’s last price of $0.31) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

MRNS Price Target

The average price target for Marinus Pharmaceuticals (MRNS) is $3.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $2.00. This represents a potential 1093.50% upside from MRNS's last price of $0.31.

MRNS Analyst Ratings

Buy

According to 5 Wall Street analysts, Marinus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MRNS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Marinus Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 23, 2024	Jay Olson	Oppenheimer	$6.00	$1.67	259.28%	1851.22%
Apr 16, 2024	Brian Skorney	Robert W. Baird	$2.00	$1.30	53.85%	550.41%
Apr 15, 2024	Sector Perform	RBC Capital	$3.00	$1.42	112.01%	875.61%
Mar 28, 2024	Jay Olson	Oppenheimer	$9.00	$9.04	-0.44%	2826.83%

Row per page

Go to

The latest Marinus Pharmaceuticals stock forecast, released on Sep 23, 2024 by Jay Olson from Oppenheimer, set a price target of $6.00, which represents a 259.28% increase from the stock price at the time of the forecast ($1.67), and a 1851.22% increase from MRNS last price ($0.31).

Marinus Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	4
Avg Price Target	-	$6.00	$5.00
Last Closing Price	$0.31	$0.31	$0.31
Upside/Downside	-100.00%	1851.22%	1526.02%

In the current month, the average price target of Marinus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Marinus Pharmaceuticals's last price of $0.31. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	JMP Securities	-	Market Perform	Downgrade
Sep 23, 2024	Cowen & Co.	Buy	Buy	Hold
Sep 23, 2024	Oppenheimer	Underperform	Outperform	Upgrade
Aug 14, 2024	Cowen & Co.	Buy	Buy	Hold
May 07, 2024	Oppenheimer	Underperform	Underperform	Hold
May 07, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Apr 16, 2024	RBC Capital	Sector Perform	Sector Perform	Hold
Apr 16, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Apr 15, 2024	RBC Capital	Outperform	Sector Perform	Downgrade
Mar 28, 2024	Oppenheimer	Perform	Perform	Hold

Row per page

Go to

Marinus Pharmaceuticals's last stock rating was published by JMP Securities on Oct 24, 2024. The company Downgrade its MRNS rating from "null" to "Market Perform".

Marinus Pharmaceuticals Financial Forecast

Marinus Pharmaceuticals Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$7.34M	$6.08M	$10.38M	$7.16M	$2.34M	$1.79M	$14.19M	$1.52M	$10.11M
Avg Forecast	$65.70M	$63.17M	$63.17M	$60.65M	$34.71M	$33.37M	$33.37M	$32.04M	$12.85M	$12.36M	$12.36M	$11.86M	$13.71M	$10.63M	$9.67M	$8.61M	$11.40M	$9.42M	$9.58M	$9.04M	$8.01M	$6.32M	$5.73M	$5.78M	$9.15M	$25.76M	$2.28M	$2.27M	$3.37M	$5.16M
High Forecast	$82.81M	$79.63M	$79.63M	$76.44M	$43.75M	$42.07M	$42.07M	$40.38M	$16.20M	$15.58M	$15.58M	$14.95M	$17.28M	$13.40M	$12.19M	$9.41M	$18.17M	$11.88M	$9.58M	$9.04M	$9.76M	$6.34M	$7.22M	$7.29M	$11.53M	$25.76M	$2.28M	$2.27M	$3.37M	$5.16M
Low Forecast	$55.86M	$53.71M	$53.71M	$51.57M	$29.51M	$28.38M	$28.38M	$27.24M	$10.93M	$10.51M	$10.51M	$10.09M	$11.66M	$9.04M	$8.22M	$7.52M	$8.87M	$8.01M	$9.58M	$9.04M	$6.90M	$6.30M	$4.87M	$4.92M	$7.78M	$25.76M	$2.28M	$2.27M	$3.37M	$5.16M
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	5	4	8	4	5	4	4	3	4	3	5	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.16%	1.06%	1.80%	0.78%	0.09%	0.78%	6.24%	0.45%	1.96%

Marinus Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 8 analysts is $8.01M, with a low forecast of $6.90M, and a high forecast of $9.76M. MRNS's average Quarter revenue forecast represents a 9.09% increase compared to the company's last Quarter revenue of $7.34M (Sep 23).

Marinus Pharmaceuticals EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	5	4	8	4	5	4	4	3	4	3	5	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-31.65M	$-31.44M	$-30.58M	$-28.98M	$77.83M	$-36.68M	$-17.58M	$-27.02M	$-18.74M
Avg Forecast	$-28.90M	$-27.79M	$-27.79M	$-26.68M	$-15.27M	$-14.68M	$-14.68M	$-14.09M	$-5.65M	$-5.44M	$-5.44M	$-5.22M	$-6.03M	$-4.68M	$-4.25M	$-3.79M	$-5.01M	$-4.14M	$-4.21M	$-3.98M	$-3.52M	$-2.78M	$-2.52M	$-2.54M	$-4.02M	$-11.47M	$-1.02M	$-24.41M	$-1.50M	$-2.30M
High Forecast	$-24.58M	$-23.63M	$-23.63M	$-22.68M	$-12.98M	$-12.48M	$-12.48M	$-11.98M	$-4.81M	$-4.62M	$-4.62M	$-4.44M	$-5.13M	$-3.98M	$-3.62M	$-3.31M	$-3.90M	$-3.52M	$-4.21M	$-3.98M	$-3.04M	$-2.77M	$-2.14M	$-2.16M	$-3.42M	$-11.47M	$-1.02M	$-19.53M	$-1.50M	$-2.30M
Low Forecast	$-36.43M	$-35.03M	$-35.03M	$-33.63M	$-19.25M	$-18.51M	$-18.51M	$-17.77M	$-7.13M	$-6.85M	$-6.85M	$-6.58M	$-7.60M	$-5.90M	$-5.36M	$-4.14M	$-7.99M	$-5.22M	$-4.21M	$-3.98M	$-4.30M	$-2.79M	$-3.18M	$-3.21M	$-5.07M	$-11.47M	$-1.02M	$-29.29M	$-1.50M	$-2.30M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.39%	12.47%	12.03%	7.20%	-6.79%	36.13%	0.72%	18.03%	8.16%

4 analysts predict MRNS's average Quarter EBITDA for Dec 22 to be $-4.02M, with a high of $-3.42M and a low of $-5.07M. This is -105.17% lower than Marinus Pharmaceuticals's previous annual EBITDA (Sep 22) of $77.83M.

Marinus Pharmaceuticals Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	5	4	8	4	5	4	4	3	4	3	5	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-32.97M	$-33.47M	$-34.57M	$-34.31M	$73.29M	$-42.09M	$-21.05M	-	$-19.51M
Avg Forecast	$34.57M	$34.72M	$36.26M	$13.20M	$4.43M	$4.86M	$5.49M	$4.76M	$-5.51M	$-4.61M	$-3.87M	$-4.51M	$-6.65M	$-8.67M	$-10.46M	$-11.98M	$-16.71M	$-23.42M	$-33.79M	$-37.93M	$-35.67M	$-37.82M	$-41.55M	$-41.84M	$-35.51M	$24.79M	$-25.30M	$-26.88M	$-43.43M	$-37.32M
High Forecast	$46.28M	$46.47M	$48.54M	$17.67M	$5.93M	$6.50M	$7.35M	$6.37M	$-4.43M	$-3.71M	$-3.12M	$-3.63M	$-5.36M	$-6.99M	$-8.43M	$-4.23M	$-11.76M	$-18.86M	$-27.21M	$-30.55M	$-34.00M	$-30.46M	$-33.46M	$-33.70M	$-28.60M	$24.79M	$-25.30M	$-21.50M	$-43.43M	$-37.32M
Low Forecast	$27.84M	$27.96M	$29.20M	$10.63M	$3.57M	$3.91M	$4.42M	$3.83M	$-7.37M	$-6.17M	$-5.19M	$-6.04M	$-8.90M	$-11.61M	$-14.00M	$-18.32M	$-20.42M	$-31.35M	$-45.23M	$-50.77M	$-36.78M	$-50.63M	$-55.62M	$-56.01M	$-47.53M	$24.79M	$-25.30M	$-32.25M	$-43.43M	$-37.32M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	0.81%	0.83%	0.97%	2.96%	1.66%	0.78%	-	0.52%

Marinus Pharmaceuticals's average Quarter net income forecast for Dec 22 is $-35.51M, with a range of $-47.53M to $-28.60M. MRNS's average Quarter net income forecast represents a -148.45% decrease compared to the company's last Quarter net income of $73.29M (Sep 22).

Marinus Pharmaceuticals SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	5	4	8	4	5	4	4	3	4	3	5	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.87M	$15.72M	$15.20M	$14.66M	$13.39M	$17.06M	$11.74M	$10.62M	$9.45M
Avg Forecast	$242.17M	$232.86M	$232.86M	$223.55M	$127.94M	$123.02M	$123.02M	$118.10M	$47.37M	$45.55M	$45.55M	$43.73M	$50.53M	$39.20M	$35.64M	$31.72M	$42.01M	$34.73M	$35.31M	$33.32M	$29.51M	$23.29M	$21.13M	$21.31M	$33.72M	$94.95M	$8.41M	$8.38M	$12.41M	$19.01M
High Forecast	$305.25M	$293.51M	$293.51M	$281.77M	$161.26M	$155.06M	$155.06M	$148.86M	$59.71M	$57.41M	$57.41M	$55.12M	$63.70M	$49.40M	$44.93M	$34.67M	$66.97M	$43.78M	$35.31M	$33.32M	$35.99M	$23.35M	$26.63M	$26.86M	$42.51M	$94.95M	$8.41M	$8.38M	$12.41M	$19.01M
Low Forecast	$205.92M	$198.00M	$198.00M	$190.08M	$108.78M	$104.60M	$104.60M	$100.42M	$40.28M	$38.73M	$38.73M	$37.18M	$42.97M	$33.33M	$30.31M	$27.74M	$32.69M	$29.53M	$35.31M	$33.32M	$25.45M	$23.22M	$17.96M	$18.12M	$28.67M	$94.95M	$8.41M	$8.38M	$12.41M	$19.01M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.64%	0.74%	0.71%	0.43%	0.14%	2.03%	1.40%	0.86%	0.50%

Marinus Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $29.51M, based on 8 Wall Street analysts, with a range of $25.45M to $35.99M. The forecast indicates a 98.47% rise compared to MRNS last annual SG&A of $14.87M (Sep 23).

Marinus Pharmaceuticals EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	5	4	8	4	5	4	4	3	4	3	5	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.61	$-0.00	$-0.67	$-0.76	$1.93	$-1.13	$-0.57	-	$-0.53
Avg Forecast	$0.60	$0.61	$0.63	$0.23	$0.08	$0.08	$0.10	$0.08	$-0.10	$-0.08	$-0.07	$-0.08	$-0.12	$-0.15	$-0.18	$-0.21	$-0.29	$-0.41	$-0.59	$-0.66	$-0.62	$-0.66	$-0.73	$-0.73	$-0.62	$0.43	$-0.44	$-0.84	$-0.76	$-0.65
High Forecast	$0.81	$0.81	$0.85	$0.31	$0.10	$0.11	$0.13	$0.11	$-0.08	$-0.06	$-0.05	$-0.06	$-0.09	$-0.12	$-0.15	$-0.07	$-0.21	$-0.33	$-0.48	$-0.53	$-0.59	$-0.53	$-0.58	$-0.59	$-0.50	$0.43	$-0.44	$-0.84	$-0.76	$-0.65
Low Forecast	$0.49	$0.49	$0.51	$0.19	$0.06	$0.07	$0.08	$0.07	$-0.13	$-0.11	$-0.09	$-0.11	$-0.16	$-0.20	$-0.24	$-0.32	$-0.36	$-0.55	$-0.79	$-0.89	$-0.64	$-0.88	$-0.97	$-0.98	$-0.83	$0.43	$-0.44	$-0.84	$-0.76	$-0.65
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.92%	0.00%	0.92%	1.22%	4.44%	2.55%	0.68%	-	0.81%

According to 4 Wall Street analysts, Marinus Pharmaceuticals's projected average Quarter EPS for Dec 22 is $-0.62, with a low estimate of $-0.83 and a high estimate of $-0.50. This represents a -132.15% decrease compared to MRNS previous annual EPS of $1.93 (Sep 22).

Marinus Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
MRNS	Marinus Pharmaceuticals	$0.31	$3.67	1083.87%	Buy
PMVP	PMV Pharmaceuticals	$1.59	$18.00	1032.08%	Buy
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
IMRX	Immuneering	$2.04	$17.50	757.84%	Buy
OVID	Ovid Therapeutics	$1.03	$7.33	611.65%	Buy
CABA	Cabaletta Bio	$2.54	$16.33	542.91%	Buy
INZY	Inozyme Pharma	$2.81	$14.67	422.06%	Buy
ABOS	Acumen Pharmaceuticals	$2.39	$7.00	192.89%	Buy
ETNB	89bio	$7.99	$22.00	175.34%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
TERN	Terns Pharmaceuticals	$5.91	$14.25	141.12%	Buy
CGEM	Cullinan Oncology	$13.10	$31.50	140.46%	Buy
VKTX	Viking Therapeutics	$51.51	$102.40	98.80%	Buy
CNTB	Connect Biopharma	$0.98	$1.50	53.06%	Buy
ELVN	Enliven Therapeutics	$26.18	$39.50	50.88%	Buy
AKRO	Akero Therapeutics	$31.03	$46.00	48.24%	Buy
EWTX	Edgewise Therapeutics	$31.51	$45.00	42.81%	Buy
MIRM	Mirum Pharmaceuticals	$42.09	$57.25	36.02%	Buy
AMLX	Amylyx Pharmaceuticals	$5.22	$6.67	27.78%	Buy
MDGL	Madrigal Pharmaceuticals	$314.17	$315.75	0.50%	Buy
IKNA	Ikena Oncology	$1.68	$1.33	-20.83%	Buy

MRNS Forecast FAQ

Is Marinus Pharmaceuticals a good buy?

Yes, according to 5 Wall Street analysts, Marinus Pharmaceuticals (MRNS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of MRNS's total ratings.

What is MRNS's price target?

Marinus Pharmaceuticals (MRNS) average price target is $3.67 with a range of $2 to $6, implying a 1093.50% from its last price of $0.307. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Marinus Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for MRNS stock, the company can go up by 1093.50% (from the last price of $0.307 to the average price target of $3.67), up by 1851.22% based on the highest stock price target, and up by 550.41% based on the lowest stock price target.

Can Marinus Pharmaceuticals stock reach $0?

MRNS's average twelve months analyst stock price target of $3.67 supports the claim that Marinus Pharmaceuticals can reach $0 in the near future.

What are Marinus Pharmaceuticals's analysts' financial forecasts?

Marinus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $133.49M (high $168.26M, low $113.51M), average EBITDA is $-58.727M (high $-49.934M, low $-74.024M), average net income is $19.54M (high $26.15M, low $15.74M), average SG&A $492.07M (high $620.25M, low $418.4M), and average EPS is $0.341 (high $0.457, low $0.275). MRNS's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $252.69M (high $318.51M, low $214.86M), average EBITDA is $-111M (high $-94.52M, low $-140M), average net income is $118.74M (high $158.95M, low $95.63M), average SG&A $931.44M (high $1.17B, low $791.98M), and average EPS is $2.07 (high $2.78, low $1.67).

Did the MRNS's actual financial results beat the analysts' financial forecasts?

Based on Marinus Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $30.99M, beating the average analysts forecast of $25.84M by 19.95%. Apple's EBITDA was $-131M, beating the average prediction of $-11.366M by 1056.86%. The company's net income was $-144M, missing the average estimation of $-157M by -7.90%. Apple's SG&A was $61.15M, missing the average forecast of $95.23M by -35.79%. Lastly, the company's EPS was $-0.0027, missing the average prediction of $-2.741 by -99.90%. In terms of the last quarterly report (Sep 2023), Marinus Pharmaceuticals's revenue was $7.34M, beating the average analysts' forecast of $6.32M by 16.15%. The company's EBITDA was $-31.646M, beating the average prediction of $-2.779M by 1038.59%. Marinus Pharmaceuticals's net income was $-32.972M, missing the average estimation of $-37.823M by -12.83%. The company's SG&A was $14.87M, missing the average forecast of $23.29M by -36.16%. Lastly, the company's EPS was $-0.61, missing the average prediction of $-0.661 by -7.70%